Navigation Links
Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/9/2009

CHADDS FORD, Pa., Jan. 9 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that David Holveck, President and Chief Executive Officer of Endo, will present a corporate update at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 at 10:30 a.m. Pacific Time. The conference will be held January 12-15, 2009 in San Francisco.

A link to a live audio Webcast of the presentation may be accessed on the Endo Website at www.endo.com. The presentation will be archived for ninety days.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 PathoGenetix, ... rapid bacterial strain typing, announced today that it has ... pathogenic E. coli strains obtained from the Centers for ... Sequence Scanning™ (GSS™) technology. The findings are detailed in ... of the American Society for Microbiology in Denver on ...
(Date:5/20/2013)... UAE (PRWEB) May 21, 2013 ... consultancy specializing in “game-changing” life science and health related ... Dalia Dergham to its International Project Team. Dergham's expertise ... even greater multi-cultural depth to Grace Century as it ... the globe. , Ms. Dergham holds both an under ...
Breaking Biology Technology:Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... Ill., May 3, 2011 Landauer, Inc. (NYSE: ... and environmental radiation monitoring and the leading domestic provider of ... fiscal 2011 second quarter ended March 31, 2011.   ... grew 2 percent to $32.3 million on contribution from Medical ...
... Answering the need for global, site-focused enrollment support, ... enrollment industry, announces the expansion of its services to ... site-centric level. "The extension of our worldwide ... to assist sponsors with their global patient enrollment needs," ...
... Corporation (NASDAQ: TECH ) (Techne) announced today ... Limited and subsidiaries (Tocris), a leading supplier of reagents ... in both in-vitro and in-vivo experiments, to understand biological ... biologically active neuro- and bio-chemicals which are used by ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4Techne Corporation Announces Acquisition 5
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
(Date:5/20/2013)... conducted at the University of Bristol and published online ... sheds light on how the brain and inner ear ... School of Earth Sciences, together with Tom Hbner from ... of 150 million year old dinosaurs. , The two ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... invites you to attend its first workshop on male ... clinical practice". The workshop provides a forum ... discuss new developments. Here some of the ... outside of Europe will announce: Nature ...
... ,The American Association of Pharmaceutical Scientists (AAPS) is ... employed in industry, academia, government and other research ... dynamic international forum for the exchange of knowledge ... health. AAPS offers timely scientific programs, on-going education, ...
... 2009 / b3c newswire / - PlatformQ , ... the healthcare, education and energy markets, and LabRoots ... scientific community, today announced the initial slate of speakers ... is the first of its kind online-only conference for ...
Cached Biology News:AAPS and PhRMA co-sponsor stability workshop 2BioConference Live Attracts Major Life Science Sponsors 2BioConference Live Attracts Major Life Science Sponsors 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
... been reported in heart tissues, and ... cell culture conditions. Treatment of ... production of TIMP-4 in some cell ... produced often require concentration of cell ...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: